PSEUDOTYPED REPORTER VIRUS PARTICLES

Virology reagents for neutralization assays: ideal for therapeutic antibody and vaccine development

Critical virology reagents

20+ years virology expertise

Trusted by 100+ labs

RVP Technology    |    RVP Catalog    |      RVP Applications     |   Case Studies   |   Publications  |   FAQs

Reporter Virus Particles (RVPs): Pseudoviruses for Safe Neutralization Data

Reporter Virus Particles (RVPs) are non-replicating pseudoviruses for your BSL-2 lab. Use them in place of live virus for high-throughput viral infectivity and neutralization assays.
Cross-section schematic of pseudotyped lentiviral RVP. Viral envelope proteins stud the surface of a spherical lipid bilayer. Inside, a lentivirus heterologous core surrounds a reporter gene. Graph shows a SARS-CoV-2 pseudovirus neutralization assay, comparing serum from two patients against positive control monoclonal antibody and negative control serum.
  • Safe in a BSL-2 environment
  • Ready-to-use pseudotyped viruses
  • Quantitative (luciferase) or fluorescent (GFP) read-out
  • Quality-controlled critical reagents based on 20+ years of virology expertise

“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”

RVP Product Offerings: The Most Extensive Catalog of Reporter Virus Particles

Cross-section schematics of RVP pseudoviruses for neutralization assays. Includes multiple coronaviruses, Influenza A and B, Filovirus, Henipavirus, Dengue, and Zika.

Learn more about our most popular RVP products:

>    SARS-CoV-2 variant Reporter Virus Particles
>    Influenza Reporter Virus Particles
>    Filovirus Reporter Virus Particles
>    Dengue and Zika RVP case study

New: TiterSafe for Easy HAI Assays

Attention influenza researchers! TiterSafe is a non-in-fectious, off-the-shelf reagent that can substitute for live virus in your existing hemagglutination inhibition (HAI) assays. TiterSafe is available in seasonal, pandemic, and custom strains.
A schematic of a TiterSafe particle. Labels flag HA and NA proteins protruding from a lipid bilayer wrapped around a lentivirus core.
LEARN ABOUT TITERSAFE

Using RVPs in Your Research: Scientific & Regulatory Information

The Integral Advantage: 20+Years of Virology Experience ​

Deep expertise in virology is at the core of Integral Molecular’s 20-year history, and we have co-authored over 100+ peer-reviewed virology publications in journals including Cell, Science and Nature. With the support of NIAID, scientists at Integral Molecular have been on the forefront of combatting viral epidemics including COVID-19, Zika, Ebola, and Chikungunya. Meet our team.

Trusted by 100+ Laboratories for R&D and Clinical Trials ​

reporter virus particles

Case Studies & Publications: See how our customers have used RVPs ​

Publications Establishing RVPs as a Critical Reagent

Frequently Asked Questions

RVPs incorporate virus-specific envelope proteins that are antigenically equivalent to those of live wild-type viruses. They contain a modified genome and so are replication-incompetent and safe to use under standard safety levels (BSL-2). Once the RVPs are in your hands, you can begin your neutralization assays immediately – no need for growing and sequencing live virus.
RVPs are used for infectivity and neutralization assays, and are ideal for use in high-throughput assay formats. They are a safe (BSL-2) and efficient alternative to live virus plaque or microneutralization assays. Many customers use our RVPs to conduct sera neutralization assays to assess efficacy of their vaccine or vaccine candidate.
Luciferase and GFP are used for quantitative readouts.

Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery, and antibody discovery against viral targets.

Yes. We can produce custom RVPs to accelerate your vaccine or antibody development project, with variants of current RVPs, or for a virus of your choice. We have a team of expert scientists that acts as your partner from project initiation to delivery of RVPs. Our customized quality control services and reports meet the specific needs of your team and project.

Yes. We can produce large lots of RVPs to accommodate screening 100s or 1000s of samples in sera neutralization assays without bridging studies.

Ready To Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.

Or call (215) 966-6061